PIK3CA and breast cancer: Ipatasertib, another AKT inhibitor which was initially tested in TNBC, has been evaluated in HR-positive, HER2-negative advanced breast cancers through the IPATunity 130 randomized phase III trial, among patients with PIK3CA/AKT1/PTEN altered tumors.